AKBA - Akebia Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
10.29
-0.22 (-2.09%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close10.51
Open10.51
Bid10.40 x 1000
Ask10.98 x 900
Day's Range10.14 - 10.69
52 Week Range7.90 - 20.25
Volume354,718
Avg. Volume535,136
Market Cap585.644M
Beta1.87
PE Ratio (TTM)N/A
EPS (TTM)-1.22
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.00
Trade prices are not sourced from all markets
  • GlobeNewswire14 days ago

    INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Keryx Biopharmaceuticals, Inc. to Akebia Therapeutics, Inc. is Fair to Shareholders

    NEW YORK, July 06, 2018-- The following statement is being issued by Levi & Korsinsky, LLP:. To: All Persons or Entities who purchased Keryx Biopharmaceuticals, Inc. stock prior to June 28, 2018. You are ...

  • Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More
    Zacks15 days ago

    Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More

    Key headlines in the biotech sector last week include Gilead getting positive CHMP opinion, Keryx plunging on merger news while Celgene and Amgen came out with pipeline updates.

  • Business Wire18 days ago

    Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted six newly-hired employees options to purchase an aggregate of 12,050 shares of Akebia’s common stock on June 29, 2018, as inducements material to each such employee’s entering into employment with Akebia. The options have an exercise price of $9.98 per share, which is equal to the closing price of Akebia’s common stock on the grant date. Each stock option vests over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with the company.

  • PR Newswire21 days ago

    WeissLaw LLP Investigates Keryx Biopharmaceuticals Inc.

    NEW YORK , June 29, 2018 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Keryx Biopharmaceuticals Inc. ("KERX" ...

  • Keryx (KERX) Inks Merger Deal With Akebia, Shares Fall
    Zacks22 days ago

    Keryx (KERX) Inks Merger Deal With Akebia, Shares Fall

    Keryx Biopharmaceuticals (KERX) enters into a definitive merger agreement with Akebia Therapeutics, Inc. under which the companies will combine in an all-stock merger.

  • Here's Why Keryx Biopharmaceuticals and Akebia Therapeutics Are Plunging Today
    Motley Fool23 days ago

    Here's Why Keryx Biopharmaceuticals and Akebia Therapeutics Are Plunging Today

    Shares of both companies tumble after the two entities announced the signing of a merger agreement. Here's what investors need to know.

  • Akebia Therapeutics and Keryx Biopharmaceuticals’ Proposed Merger
    Market Realist23 days ago

    Akebia Therapeutics and Keryx Biopharmaceuticals’ Proposed Merger

    The companies are to form a new, fully integrated company focused on chronic kidney diseases (or CKD) called Akebia Therapeutics. If Keryx Biopharmaceuticals manages to completely convert its outstanding convertible notes, the pro forma equity value of the combined company would be $1.3 billion, based on the closing share prices of the companies yesterday. Keryx is to add Auryxia, a drug approved by the FDA for hyperphosphatemia in CKD patients dependent on dialysis and for iron deficiency anemia in CKD patients not dependent on dialysis, to Akebia Therapeutics’ product portfolio.

  • Business Wire23 days ago

    Akebia Therapeutics and Keryx Biopharmaceuticals to Merge, Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease

    Akebia Therapeutics, Inc. (AKBA) and Keryx Biopharmaceuticals, Inc. (KERX) today announced that the companies signed, and the boards of directors of both companies have unanimously approved, a definitive merger agreement under which the companies will combine in an all-stock merger. The transaction will create a fully integrated biopharmaceutical company focused on chronic kidney disease (CKD), with an implied pro forma equity value of approximately $1.3 billion, assuming full conversion of Keryx’s outstanding convertible notes, based on the closing prices of Keryx and Akebia on June 27, 2018. The combined company will be named Akebia Therapeutics, Inc.

  • Ex-Akebia employee jailed for night as insider trading trial starts
    Reuters24 days ago

    Ex-Akebia employee jailed for night as insider trading trial starts

    A former Akebia Therapeutics Inc (AKBA.O) employee accused of engaging in an insider trading scheme must spend a night in jail after he violated a U.S. judge's order and spoke to a witness at the start of his trial on Tuesday. U.S. District Judge Indira Talwani in Boston ordered the detention of Schultz Chan, who has had prior issues following court directives, after asking why he could not heed her warnings to not talk to witnesses, as he did by saying hello to one. The development occurred shortly after jurors heard opening statements in the trial of Chan and Songjiang Wang, a former Merrimack Pharmaceuticals Inc (MACK.O) employee who prosecutors say participated in the insider trading scheme with Chan.

  • ACCESSWIRElast month

    Today’s Free Research Reports Coverage on Agenus and Three More Biotech Stocks

    In today's pre-market research, WallStEquities.com evaluates Affimed N.V. (NASDAQ: AFMD), Agenus Inc. (NASDAQ: AGEN), Akcea Therapeutics Inc. (AKCA), and Akebia Therapeutics Inc. (NASDAQ: AKBA). The Company's shares are trading 8.38% above their 200-day moving average.

  • GlobeNewswirelast month

    Investor Expectations to Drive Momentum within Core-Mark Holding, SSR Mining, iRhythm Technologies, Magic Software Enterprises, Jounce Therapeutics, and Akebia Therapeutics — Discovering Underlying Factors of Influence

    NEW YORK, June 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Core-Mark ...

  • Business Wire2 months ago

    Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted four newly-hired employees options to purchase an aggregate of 21,300 shares of Akebia’s common stock on May 31, 2018, as inducements material to each such employee’s entering into employment with Akebia. The options have an exercise price of $9.82 per share, which is equal to the closing price of Akebia’s common stock on the grant date. Each stock option vests over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with the company.

  • Business Wire2 months ago

    Akebia Therapeutics to Present at Upcoming Investor Conference

    Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that its President and Chief Executive Officer, John P. Butler, will present at the UBS Global Healthcare Conference on Tuesday, May 22, 2018, at 4:00 p.m. Eastern Time, at the Grand Hyatt New York in New York City. Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology.

  • Associated Press2 months ago

    Akebia Therapeutics: 1Q Earnings Snapshot

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 48 cents. The kidney disease treatment developer posted revenue of $45.9 million in the period. Akebia Therapeutics ...

  • Business Wire3 months ago

    Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted five newly-hired employees options to purchase an aggregate of 10,450 shares of Akebia’s common stock on April 30, 2018, as inducements material to each such employee’s entering into employment with Akebia. The options have an exercise price of $9.21 per share, which is equal to the closing price of Akebia’s common stock on the grant date. Each stock option vests over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with the company.

  • Business Wire4 months ago

    Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Akebia Therapeutics, Inc. , a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor , granted 13 newly-hired employees options to purchase an aggregate of 63,000 shares of Akebia’s common stock on March 29, 2018, as inducements material to each such employee’s entering into employment with Akebia.

  • Analysts’ Ratings for Athenex and Its Peers in March
    Market Realist4 months ago

    Analysts’ Ratings for Athenex and Its Peers in March

    What's behind Athenex's Superior Performance in 2018?Athenex

  • Business Wire4 months ago

    Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

    Akebia Therapeutics, Inc. , a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor , today announced the pricing of an underwritten public offering of 8,500,000 shares of common stock at a price to the public of $10.50 per share.

  • Business Wire4 months ago

    Akebia Therapeutics Announces Proposed Public Offering of Common Stock

    Akebia Therapeutics, Inc.  , a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor , today announced that it intends to offer and sell approximately $85 million of shares of its common stock in an underwritten public offering.

  • Business Wire4 months ago

    Akebia Therapeutics to Present at Upcoming Investor Conferences

    Akebia Therapeutics, Inc. , a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-induc

  • ACCESSWIRE4 months ago

    Blog Exposure - Chiasma to Present Design of Phase-3 Double-Blind Trial of Oral Octreotide Capsules Versus Placebo in Acromegaly Patients at ENDO 2018

    Stock Monitor: Akebia Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 20, 2018 / Active-Investors.com has just released a free research report on Chiasma, Inc. (NASDAQ: CHMA ). If ...

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of AKBA earnings conference call or presentation 12-Mar-18 8:30pm GMT

    Q4 2017 Akebia Therapeutics Inc Earnings Call